68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level  | Zendy

Lars J. Petersen | Zendy; Julie B. Nielsen | Zendy; Katja Dettmann | Zendy; Rune Vincents Fisker | Zendy; Uwe Haberkorn | Zendy; Louise Stenholt | Zendy; Helle D. Zacho | Zendy

Open Access

68Ga-PSMA PET/CT for the detection of bone metastasis in recurrent prostate cancer and a PSA level <2 ng/ml: Two case reports and a literature review

Author(s) -

Lars J. Petersen,

Julie B. Nielsen,

Katja Dettmann,

Rune Vincents Fisker,

Uwe Haberkorn,

Louise Stenholt,

Helle D. Zacho

Publication year - 2017

Publication title -

molecular and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.442

H-Index - 7

eISSN - 2049-9469

pISSN - 2049-9450

DOI - 10.3892/mco.2017.1280

Subject(s) - prostate cancer , medicine , biochemical recurrence , positron emission tomography , cancer , androgen deprivation therapy , magnetic resonance imaging , bone metastasis , glutamate carboxypeptidase ii , prostate , metastasis , prostate specific antigen , nuclear medicine , radiology , oncology , prostatectomy

Localization of prostate cancer recurrence, particularly in the bones, is a major challenge with standard of care imaging in patients with biochemical recurrence following curatively intended treatment. Gallium-68-labeled prostate specific membrane antigen positron emission tomography/computed tomography ( 68 Ga-PSMA PET/CT) is a novel and promising method for imaging in prostate cancer. The present study reports two cases of patients with prostate cancer with biochemical recurrence, with evidence of bone metastases on 68 Ga-PSMA PET/CT images and low prostate specific antigen PSA levels (<2 ng/ml) and PSA doubling time >6 months. The bone metastases were verified by supplementary imaging with 18 F-sodium fluoride PET/CT and magnetic resonance imaging as well as biochemical responses to androgen deprivation therapy. Therefore, 68 Ga-PSMA PET/CT is promising for the restaging of patients with prostate cancer with biochemical recurrence, including patients with low PSA levels and low PSA kinetics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research